Eisai Unveils Sales Projections for Leqembi® at Investor Relations Day

On May 25, 2026, BioArctic AB’s partner, Eisai, presented a detailed simulation forecasting the potential future sales of Leqembi® during its Investor Relations Day. This event showcased the financial outlook for this pioneering Alzheimer’s treatment, which has been the result of a long-standing collaboration between BioArctic and Eisai.

According to Eisai’s simulation, Leqembi sales are projected to reach approximately JPY 300 billion, equivalent to around SEK 17.6 billion, for the fiscal year ending March 2029. This impressive figure highlights the increasing demand and market potential for the drug, reflecting its status as a groundbreaking therapy in the Alzheimer's space.

Leqembi®, or lecanemab, represents a significant achievement in Alzheimer’s treatment, being the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's patients. The product has already gained approval in 53 countries and is undergoing regulatory review in six others.

Understanding Leqembi®

Leqembi is a humanized IgG1 monoclonal antibody that targets aggregated soluble and insoluble amyloid-beta forms, which are critical in Alzheimer’s disease. This therapy involves an initial treatment phase administered every two weeks for 18 months, followed by maintenance dosing every four weeks, which is already approved in several countries, including the US and Japan.

Furthermore, innovations surrounding Leqembi are ongoing. In January 2026, Eisai received priority review status from the US FDA for a subcutaneous formulation of the treatment, aiming to enhance patient accessibility and convenience.

The drug's inclusion in China's 'Commercial Insurance Innovative Drug List' in late 2025 indicates its growing recognition and acceptance within international markets, further affirming its value in clinical practice. The latest updates also reveal ongoing clinical trials exploring Leqembi's effectiveness in patients with preclinical Alzheimer’s disease, ensuring that research continues to evolve.

Long-term Collaboration: BioArctic and Eisai

The relationship between BioArctic and Eisai dates back to 2005, with a focus on developing and commercializing Alzheimer’s therapies. Notable agreements include the pivotal 2007 Development and Commercialization agreement for lecanemab and a follow-up contract for its backup. BioArctic holds rights to commercialize Leqembi in the Nordic regions while benefiting from milestone payments and royalties from global sales.

Eisai's responsibility includes overseeing clinical developments and regulatory approvals for the therapeutic, which has positioned the firm as a leader in the Alzheimer's treatment landscape. This partnership not only illustrates a strong synergy between the two companies but also underscores the potential for future advancements in treating neurodegenerative diseases.

BioArctic's Vision

BioArctic AB is a biopharmaceutical company dedicated to innovative therapeutics aimed at altering the course of neurodegenerative diseases. Beyond Leqembi, the company has a robust portfolio targeting illnesses like Parkinson’s disease and ALS, showcasing their commitment to addressing significant healthcare challenges. Their proprietary BrainTransporter™ technology aims to revolutionize the ability of treatment antibodies to cross the blood-brain barrier, enhancing efficacy in neurodegenerative disease therapies.

As the market evolves and Alzheimer's treatment gains attention, Eisai’s sales projections signal a promising horizon for Leqembi. With the partnership between BioArctic and Eisai firmly established and expanding, the landscape of Alzheimer’s disease management continues to shift towards more effective solutions, offering hope to millions impacted by these challenging conditions.